Dipeptidyl peptidase 4 inhibitors vs. metformin for new-onset dementia: a propensity score-matched cohort study
CONCLUSION: In this real-world study, we found that DPP4 inhibitors presented an association with a lower risk of dementia in individuals with type 2 diabetes than metformin, particularly in older people and those without diabetes-related comorbidities.PMID:38652239 | DOI:10.1210/clinem/dgae281 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 23, 2024 Category: Endocrinology Authors: Siyang Liu Heng Wan Sheng Nie Huanyi Cao Lan Liu Hua Liang Hong Xu Bicheng Liu Chunbo Chen Huafeng Liu Qiongqiong Yang Hua Li Yaozhong Kong Guisen Li Qijun Wan Yan Zha Ying Hu Gang Xu Yongjun Shi Yilun Zhou Guobin Su Ying Tang Mengchun Gong Aixin Guo Jian Source Type: research
Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial
CONCLUSION: Early combination triple therapy showed better efficacy and durability than the single add-on (dual) therapy. Therefore, combination therapy with metformin, alogliptin, and pioglitazone is a valuable early treatment option for T2DM poorly controlled with metformin monotherapy.PMID:38650099 | DOI:10.4093/dmj.2023.0259 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - April 23, 2024 Category: Endocrinology Authors: Ji-Yeon Park Joonyub Lee Yoon-Hee Choi Kyung Wan Min Kyung Ah Han Kyu Jeung Ahn Soo Lim Young-Hyun Kim Chul Woo Ahn Kyung Mook Choi Kun-Ho Yoon Practical Evidence of Antidiabetic Combination Therapy in Korea (PEAK) study investigators Source Type: research
Dipeptidyl peptidase 4 inhibitors vs. metformin for new-onset dementia: a propensity score-matched cohort study
CONCLUSION: In this real-world study, we found that DPP4 inhibitors presented an association with a lower risk of dementia in individuals with type 2 diabetes than metformin, particularly in older people and those without diabetes-related comorbidities.PMID:38652239 | DOI:10.1210/clinem/dgae281 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - April 23, 2024 Category: Endocrinology Authors: Siyang Liu Heng Wan Sheng Nie Huanyi Cao Lan Liu Hua Liang Hong Xu Bicheng Liu Chunbo Chen Huafeng Liu Qiongqiong Yang Hua Li Yaozhong Kong Guisen Li Qijun Wan Yan Zha Ying Hu Gang Xu Yongjun Shi Yilun Zhou Guobin Su Ying Tang Mengchun Gong Aixin Guo Jian Source Type: research
Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial
CONCLUSION: Early combination triple therapy showed better efficacy and durability than the single add-on (dual) therapy. Therefore, combination therapy with metformin, alogliptin, and pioglitazone is a valuable early treatment option for T2DM poorly controlled with metformin monotherapy.PMID:38650099 | DOI:10.4093/dmj.2023.0259 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - April 23, 2024 Category: Endocrinology Authors: Ji-Yeon Park Joonyub Lee Yoon-Hee Choi Kyung Wan Min Kyung Ah Han Kyu Jeung Ahn Soo Lim Young-Hyun Kim Chul Woo Ahn Kyung Mook Choi Kun-Ho Yoon Practical Evidence of Antidiabetic Combination Therapy in Korea (PEAK) study investigators Source Type: research
Management of Type 2 Diabetes Mellitus With Noninsulin Pharmacotherapy
Am Fam Physician. 2024 Apr;109(4):333-342.ABSTRACTType 2 diabetes mellitus is a chronic disease that is increasing in global prevalence. An individualized approach to pharmacotherapy should consider costs, benefits beyond glucose control, and adverse events. Metformin is the first-line therapy due to its low cost and effectiveness. Sulfonylureas and thiazolidinediones are additional low-cost oral hypoglycemic classes available in the United States; however, evidence shows variability in weight gain and hypoglycemia. Thiazolidinediones increase fluid retention and are not recommended in patients with New York Heart Associat...
Source: American Family Physician - April 22, 2024 Category: Primary Care Authors: Elizabeth M Vaughan Zuleica M Santiago-Delgado Source Type: research
Management of Type 2 Diabetes Mellitus With Noninsulin Pharmacotherapy
Am Fam Physician. 2024 Apr;109(4):333-342.ABSTRACTType 2 diabetes mellitus is a chronic disease that is increasing in global prevalence. An individualized approach to pharmacotherapy should consider costs, benefits beyond glucose control, and adverse events. Metformin is the first-line therapy due to its low cost and effectiveness. Sulfonylureas and thiazolidinediones are additional low-cost oral hypoglycemic classes available in the United States; however, evidence shows variability in weight gain and hypoglycemia. Thiazolidinediones increase fluid retention and are not recommended in patients with New York Heart Associat...
Source: American Family Physician - April 22, 2024 Category: Primary Care Authors: Elizabeth M Vaughan Zuleica M Santiago-Delgado Source Type: research
Management of Type 2 Diabetes Mellitus With Noninsulin Pharmacotherapy
Am Fam Physician. 2024 Apr;109(4):333-342.ABSTRACTType 2 diabetes mellitus is a chronic disease that is increasing in global prevalence. An individualized approach to pharmacotherapy should consider costs, benefits beyond glucose control, and adverse events. Metformin is the first-line therapy due to its low cost and effectiveness. Sulfonylureas and thiazolidinediones are additional low-cost oral hypoglycemic classes available in the United States; however, evidence shows variability in weight gain and hypoglycemia. Thiazolidinediones increase fluid retention and are not recommended in patients with New York Heart Associat...
Source: American Family Physician - April 22, 2024 Category: Primary Care Authors: Elizabeth M Vaughan Zuleica M Santiago-Delgado Source Type: research
Management of Type 2 Diabetes Mellitus With Noninsulin Pharmacotherapy
Am Fam Physician. 2024 Apr;109(4):333-342.ABSTRACTType 2 diabetes mellitus is a chronic disease that is increasing in global prevalence. An individualized approach to pharmacotherapy should consider costs, benefits beyond glucose control, and adverse events. Metformin is the first-line therapy due to its low cost and effectiveness. Sulfonylureas and thiazolidinediones are additional low-cost oral hypoglycemic classes available in the United States; however, evidence shows variability in weight gain and hypoglycemia. Thiazolidinediones increase fluid retention and are not recommended in patients with New York Heart Associat...
Source: American Family Physician - April 22, 2024 Category: Primary Care Authors: Elizabeth M Vaughan Zuleica M Santiago-Delgado Source Type: research
Management of Type 2 Diabetes Mellitus With Noninsulin Pharmacotherapy
Am Fam Physician. 2024 Apr;109(4):333-342.ABSTRACTType 2 diabetes mellitus is a chronic disease that is increasing in global prevalence. An individualized approach to pharmacotherapy should consider costs, benefits beyond glucose control, and adverse events. Metformin is the first-line therapy due to its low cost and effectiveness. Sulfonylureas and thiazolidinediones are additional low-cost oral hypoglycemic classes available in the United States; however, evidence shows variability in weight gain and hypoglycemia. Thiazolidinediones increase fluid retention and are not recommended in patients with New York Heart Associat...
Source: American Family Physician - April 22, 2024 Category: Primary Care Authors: Elizabeth M Vaughan Zuleica M Santiago-Delgado Source Type: research
Management of Type 2 Diabetes Mellitus With Noninsulin Pharmacotherapy
Am Fam Physician. 2024 Apr;109(4):333-342.ABSTRACTType 2 diabetes mellitus is a chronic disease that is increasing in global prevalence. An individualized approach to pharmacotherapy should consider costs, benefits beyond glucose control, and adverse events. Metformin is the first-line therapy due to its low cost and effectiveness. Sulfonylureas and thiazolidinediones are additional low-cost oral hypoglycemic classes available in the United States; however, evidence shows variability in weight gain and hypoglycemia. Thiazolidinediones increase fluid retention and are not recommended in patients with New York Heart Associat...
Source: American Family Physician - April 22, 2024 Category: Primary Care Authors: Elizabeth M Vaughan Zuleica M Santiago-Delgado Source Type: research
An in vitro study of metformin adsorption to activated charcoal
. (Source: Clinical Toxicology)
Source: Clinical Toxicology - April 22, 2024 Category: Toxicology Authors: Yoshinori TomodaMasahiro KobayashiLaboratory of Clinical Pharmacokinetics, Research and Education Center for Clinical Pharmacy, Kitasato University School of Pharmacy, Tokyo, Japan Source Type: research
Targeting dysregulated lipid metabolism for the treatment of Alzheimer's disease and Parkinson's disease: Current advancements and future prospects
Neurobiol Dis. 2024 Apr 18:106505. doi: 10.1016/j.nbd.2024.106505. Online ahead of print.ABSTRACTAlzheimer's and Parkinson's diseases are two of the most frequent neurological diseases. The clinical features of AD are memory decline and cognitive dysfunction, while PD mainly manifests as motor dysfunction such as limb tremors, muscle rigidity abnormalities, and slow gait. Abnormalities in cholesterol, sphingolipid, and glycerophospholipid metabolism have been demonstrated to directly exacerbate the progression of AD by stimulating Aβ deposition and tau protein tangles. Indirectly, abnormal lipids can increase the burden o...
Source: Neurobiology of Disease - April 20, 2024 Category: Neurology Authors: Bin Tong Yaoqi Ba Zhengyang Li Caidi Yang Kangtai Su Haodong Qi Deju Zhang Xiao Liu Yuting Wu Yixuan Chen Jitao Ling Jing Zhang Peng Yu Xiaoping Yin Source Type: research
